D. Parker Kelley, PhD

D. Parker Kelley, PhD

@sequencemyneuro.bsky.social

Associate Research Scientist in Picard lab @ Columbia University Irving Medical Center Mitochondrial Psychobiology, Psychoneuroimmuno, Stress, PTSD & Psychedelics https://youtube.com/playlist?list=PL4Ay4xZzeUu6177ir3UeJZzUL059jR3w3&si=cMaJpyOXiFNBfCSX

302 followers220 following71 posts

Perhaps its better to classify psychedelics as "immunomodulatory"? In a paper titled "Allostatic Recalibration Theory (ART)", we proposed such a mechanism called "Allostatic Recalibration"(under review- see preprint for detail).

Critically, this context-dependence could potentially be explained by floor effects and the lower limit of detection of the assays used in these studies and direct comparisons and large human clinical trials in populations with elevated inflammation are needed.

Do these effects differ from other anti-inflammatories? -Very high or chronic dosing of glucocorticoids are immunosupressive, a major limitation. Alternatively, every study that used extreme (> 5mg/kg) or chronic doses of psychedelics observed modest pro-inflammatory effects.

-We hypothesize that psychedelics produce unique context-dependent anti-inflammatory effects in inflammatory contexts, but mixed* effects in healthy organisms because they act through a distinct mechanism from canonical anti-inflammatories.

Mixed effects in healthies, but anti-inflammatory effects in participants with elevated baseline inflammation, or inflammatory diseases, including in our upcoming short report of psilocybin immune and mitochondrial effects in an open label trail of Parkinson's disease (in press- stay tuned!).

We observed consistent, but context-dependent anti-inflammatory effects of psychedelics in in vitro and in vivo murine inflammatory models (SMD = -1.23), but no effect in non-inflammatory in vivo murine models (SMD = -0.06).

I love this so much. All biomedical research institutions should pay homage to our model organisms who have and will continue to save countless lives and advance our understanding of ourselves into the future!

Annika Barber@annikabarber.bsky.social

Took a selfie with the tiniest statue paying tribute to model organisms in science! 🧪 🐭 🐟 🪰🪱

D. Parker Kelley, PhD reposted

*Neuroscience and philosophy* Given the philosophical/conceptual naivete of all of neuroscience I will be retiring from my faculty position. I'm now looking for positions at philosophy departments and am happy to start at any level. I went from faculty to postdoc before and am ready again.

D. Parker Kelley, PhD reposted

Lovely work on autoimmunity and its link to psychosis. I wonder what effect this modulation of NMDA receptors has on HALIPs? Less PPI would seem to be the opposite of a strong prior?

Katharina Schmack @kathaschmack.bsky.social

🥁🎉The Psychosis Collective proudly presents our first preprint 𝐂𝐥𝐨𝐳𝐚𝐩𝐢𝐧𝐞 𝐬𝐮𝐩𝐩𝐫𝐞𝐬𝐬𝐞𝐬 𝐚𝐮𝐭𝐨𝐢𝐦𝐦𝐮𝐧𝐢𝐭𝐲 𝐝𝐫𝐢𝐯𝐢𝐧𝐠 𝐩𝐬𝐲𝐜𝐡𝐨𝐬𝐢𝐬-𝐥𝐢𝐤𝐞 𝐛𝐞𝐡𝐚𝐯𝐢𝐨𝐮𝐫 𝐢𝐧 𝐦𝐢𝐜𝐞 𝘈 𝘥𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺 𝘫𝘰𝘶𝘳𝘯𝘦𝘺 𝘪𝘯 𝘵𝘩𝘳𝘦𝘦 𝘢𝘤𝘵𝘴 starring Le He & Harriet Feldman www.biorxiv.org/content/10.6... We wanted to understand how antipsychotics work. Thread🧵

D. Parker Kelley, PhD reposted

Replying to @eikofried.bsky.social

Overall, I am very grateful to EIC Dost Ongur for letting me write the paper I wanted to write! Feedback very welcome—I submitted a medium size personalize grant on this topic in the Netherlands now to do this 'HPCing' in large-scale data.

D. Parker Kelley, PhD reposted

Hey friends, my new paper was just published in JAMA Psychiatry. I draw on biological species classification to sketch a new framework for psychiatric nosology. Brief summary follows below. Full text link: jamanetwork.com/journals/jam... 🧪 #PsychSciSky #MentalHealth

jamanetwork.comMental Disorders as Homeostatic Property ClustersThis narrative review explores the idea of understanding mental disorders according to homeostatic property clusters rather than through typical classification systems.

D. Parker Kelley, PhD reposted

𝗛𝗼𝘄 𝗱𝗼 𝗯𝗿𝗮𝗶𝗻 𝗮𝗿𝗲𝗮𝘀 𝗿𝗲𝗹𝗮𝘁𝗲𝗱 𝘁𝗼 𝗳𝘂𝗻𝗰𝘁𝗶𝗼𝗻? "High-resolution activity maps of PFC did NOT align with cytoarchitecturally defined subregions." Key tenet in neuroscience is that cytoarchitectonic boundaries correspond to functional ones. NB: study in the mouse #neuroskyence doi.org/10.1038/s415...

Please use full factorial designs in preclinical psychedelic research! I'm guilty of not doing so in the past, but it will be critical for understanding their MOA going forward. We need to be able to directly compare effects in pathology to those healthy organisms

D. Parker Kelley, PhD reposted

Replying to @sequencemyneuro.bsky.social

Excellent interview... VERY interesting insights on stress vs mitochodrial energy balance. I wonder how much impact on stress adaptation can be gained by increasing mitochondrial resilience w keto/low carb/ Fasting and the right amount of Exercise stress (hiit, resistance trng)

D. Parker Kelley, PhD reposted

Wait so midazolam is an antidepressant? Wut?

Eiko Fried@eikofried.bsky.social

New 6-month depression RCT in n=65, serial Ketamine infusions as adjunctive care vs active placebo midazolam. Ketamine did not outperform primary nor any of the secondary efficacy, cognitive, economic, or quality-of-life outcomes. 🧪 #psychiary #PsychSciSky jamanetwork.com/journals/jam...

D. Parker Kelley, PhD reposted

Hot off the press!

D. Parker Kelley, PhD@sequencemyneuro.bsky.social

🚨Publication alert! 🚨 Why does stress drive psychopathology & transdiagnostic disease? We present the Allostatic Triage Model of Psychopathology (ATP Model), which explains stress-induced transdiagnostic disease pathogenesis through a bioenergetic lens. www.sciencedirect.com/science/arti...

View full thread

We propose that metabolic stress drives allostatic triage to stress-responsive networks that ensure short-term survival, like the salience network, from other networks including the central executive network that supports executive and goal-oriented functions, driving psychiatric symptoms

Altogether, we propose that extreme or chronic stress dysregulates mitochondria, affect, and allostatic triage, impairing allostasis, and driving transdiagnostic pathological states that, over time, become entrenched or "canalized" into pathological transdiagnostic disease phenotypes.

View full thread

In the ATP Model, we introduce a novel concept- Allostatic Triage: the stress-induced reallocation of CNS metabolic resources from expensive executive control networks that optimize long term outcomes to less expensive networks optimized for short-term survival, like the salience network

D. Parker Kelley, PhD reposted

D. Parker Kelley, PhD reposted

I'm near certain sLFOs are big for psychedelics.

Cole Korponay@ckorponay.bsky.social

An exciting 🆕 extension of our sLFO/FC inflation work (www.nature.com/articles/s41...) Extracting the sLFO signal from BOLD data not only sharpens FC estimates.. ..the sLFO itself - via links to arousal - captures variability in trait + state drug use phenotypes: tinyurl.com/msanmrnc #neuroimaging

D. Parker Kelley, PhD reposted

Just delighted to see this out in the world !! This is the first installment of SYPRES -- our living meta-analysis + open data resource focused on psychedelics. Led by the incomparable @parkersingleton.bsky.social and @bsevchik.bsky.social. Check it out + and give us your feedback!!!

Parker Singleton@parkersingleton.bsky.social

🍄 Our new living systematic review and meta-analysis on psilocybin for depression is out. Here's what we found and the open science infrastructure we built to support it 🧪🧵 www.medrxiv.org/content/10.1...

Such a beautiful project! This is the exact sort of framework we need to advance progress going forward.

Parker Singleton@parkersingleton.bsky.social

🍄 Our new living systematic review and meta-analysis on psilocybin for depression is out. Here's what we found and the open science infrastructure we built to support it 🧪🧵 www.medrxiv.org/content/10.1...

D. Parker Kelley, PhD reposted

D. Parker Kelley, PhD reposted

Since its founding in 2021 by myself and Zarmeen Zahid as Your Brain on Science, it's expanded into Psychedelic Brain Science, to encompass the larger goal of including all things psychedelic including research, policy and culture. Now we’re expanding further to provide services! Check it out!

Psychedelic Brain Science@psychedbrainsci.bsky.social

Psychedelic Brain Science is officially an LLC! To celebrate we’re launching Psychedelic Brain Science Consulting where a variety of services will be offered including workshops, one-on-one coaching, general consulting, independent analysis, and more! For details visit our website!

D. Parker Kelley, PhD reposted

D. Parker Kelley, PhD reposted